#BEGIN_DRUGCARD DB00581

# AHFS_Codes:
40:10.00

# ATC_Codes:
A06AD11

# Absorption:
Poorly absorbed from the gastrointestinal tract as no human enzyme that is capable of hydrolysis of this disaccharide is present in human gastrointestinal tissue.

# Biotransformation:
Lactulose is completely metabolized in the colon by enteric bacteria, and no lactulose is excreted in the feces.

# Brand_Mixtures:
Not Available

# Brand_Names:
Acilac
Bifiteral
Cephulac
Cholac
Chronulac
Constilac
Constulose
D-Lactulose
Duphalac
Enulose
Evalose
Fructofuranose
Generlac
Heptalac
Isolactose
Kristalose
Lactulosa [INN-Spanish]
Lactulosa [Spanish]
Lactulose [USAN:BAN:INN:JAN]
Lactulose, ~98%
Lactulosum [INN-Latin]
Lactulosum [Latin]
Laevolac
Lattulosio [Italian]
Laxilose
Portalac

# CAS_Registry_Number:
4618-18-2

# ChEBI_ID:
6359

# Chemical_Formula:
C12H22O11

# Chemical_IUPAC_Name:
(2S,3R,4S,5R,6R)-2-{[(2R,3S,4S,5R)-4,5-dihydroxy-2,5-bis(hydroxymethyl)oxolan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
690686

# Description:
A synthetic disaccharide used in the treatment of constipation and hepatic encephalopathy. It has also been used in the diagnosis of gastrointestinal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p887)

# Dosage_Forms:
Liquid	Oral
Solution	Oral
Syrup	Oral

# Drug_Category:
Gastrointestinal Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-4.3

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
7.64E+005 mg/L (at 30 °C)

# Food_Interactions:
Take without regard to meals. Drink liberally.

# GenBank_ID:
Not Available

# Generic_Name:
Lactulose

# HET_ID:
Not Available

# Half_Life:
1.7-2 hours

# InChI_Identifier:
InChI=1S/C12H22O11/c13-1-4-6(16)7(17)8(18)11(21-4)22-9-5(2-14)23-12(20,3-15)10(9)19/h4-11,13-20H,1-3H2/t4-,5-,6+,7+,8-,9-,10+,11+,12-/m1/s1

# InChI_Key:
InChIKey=JCQLYHFGKNRPGE-FCVZTGTOSA-N

# Indication:
For the treatment of constipation and hepatic encephalopathy.

# KEGG_Compound_ID:
C07064

# KEGG_Drug_ID:
D00352

# LIMS_Drug_ID:
581

# Mechanism_Of_Action:
Lactulose is a synthetic sugar used in the treatment of constipation and liver disease. It consists of the monosaccharides fructose and galactose. In the colon, lactulose is broken down primarily to lactic acid, and also to small amounts of formic and acetic acids, by the action of via evolved-beta galactosidase from colonic bacteria, which results in an increase in osmotic pressure and slight acidification of the colonic contents. This in turn causes an increase in stool water content and softens the stool. In treating heptic diseases (hepatic encephalopathy) it is thought that lactulose draws out ammonia from the body in the same way that it draws out water into the colon.

# Melting_Point:
169 °C

# Molecular_Weight_Avg:
342.2965

# Molecular_Weight_Mono:
342.116211546

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/lac_0300.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA164748762

# Pharmacology:
Therapeutically, lactulose has laxative and ammonia-detoxifying actions. In treating constipation lactulose metabolites draw water into the bowel, causing a cathartic effect through osmotic action.

# Predicted_LogP_Hydrophobicity:
-3.3

# Predicted_LogS:
0.36

# Predicted_Water_Solubility:
7.92e+02 g/l

# Primary_Accession_No:
DB00581

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
11333

# PubChem_Substance_ID:
46506757

# RxList_Link:
http://www.rxlist.com/cgi/generic2/lactulose.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01063

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
LD<sub>50</sub>=18.2 g/kg (oral, rat). Side effects include diarrhea and resultant dehydration.

# Update_Date:
2013-02-08 16:19:28 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Lactulose

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasmic

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
3089818	Noone C, Menzies IS, Banatvala JE, Scopes JW: Intestinal permeability and lactose hydrolysis in human rotaviral gastroenteritis assessed simultaneously by non-invasive differential sugar permeation. Eur J Clin Invest. 1986 Jun;16(3):217-25.
8949640	Bjarnason I, Batt R, Catt S, Macpherson A, Maxton D, Menzies IS: Evaluation of differential disaccharide excretion in urine for non-invasive investigation of altered intestinal disaccharidase activity caused by alpha-glucosidase inhibition, primary hypolactasia, and coeliac disease. Gut. 1996 Sep;39(3):374-81.
9718732	Hall BG, Malik HS: Determining the evolutionary potential of a gene. Mol Biol Evol. 1998 Aug;15(8):1055-61.
97820	Cook GC: Breath hydrogen concentrations after oral lactose and lactulose in tropical malabsorption and adult hypolactasia. Trans R Soc Trop Med Hyg. 1978;72(3):277-81.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
M64441

# Drug_Target_1_GenBank_ID_Protein:
145821

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ebgA

# Drug_Target_1_Gene_Sequence:
>3096 bp
ATGAATCGCTGGGAAAACATTCAGCTCACCCACGAAAACCGACTTGCGCCGCGTGCGTAC
TTTTTTTCATATGATTCTGTTGCGCAAGCGCGTACCTTTGCCCGCGAAACCAGCAGCCTG
TTTCTGCCCTTAAGCGGTCAGTGGAATTTCCACTTTTTTGACCATCCGCTGCAAGTACCA
GAAGCCTTCACCTCTGAGTTAATGGCTGACTGGGGGCATATTACCGTCCCCGCCATGTGG
CAAATGGAAGGTCACGGCAAACTGCAATATACCGACGAAGGTTTTCCGTTCCCCATCGAT
GTGCCGTTTGTCCCCAGCGATAACCCAACCGGTGCCTATCAACGTATTTTCACCCTCAGC
GACGGCTGGCAGGGTAAACAGACGCTGATTAAATTTGACGGCGTCGAAACCTATTTTGAA
GTCTATGTTAACGGTCAGTATGTGGGTTTCAGCAAGGGCAGTCGCCTGACCGCAGAGTTT
GACATCAGCGCGATGGTTAAAACCGGCGACAACCTGTTGTGTGTGCGCGTGATGCAGTGG
GCGGACTCTACCTACGTGGAAGACCAGGATATGTGGTGGTCAGCGGGGATCTTCCGCGAT
GTTTATCTGGTCGGAAAACACCTAACGCATATTAACGATTTCACTGTGCGTACCGACTTT
GACGAAGCCTATTGCGATGCCACGCTTTCCTGCGAAGTGGTGCTGGAAAATCTCGCCGCC
TCCCCTGTCGTCACGACGCTGGAATATACCCTGTTTGATGGCGAACGCGTGGTGCACAGC
AGCGCCATTGATCATTTGGCAATTGAAAAACTGACCAGCGCCACGTTTGCTTTTACTGTC
GAACAGCCGCAGCAATGGTCAGCAGAATCCCCTTATCTTTACCATCTGGTCATGACGCTG
AAAGACGCCAACGGCAACGTTCTGGAAGTGGTGCCACAACGCGTTGGCTTCCGTGATATC
AAAGTGCGCGACGGTCTGTTCTGGATCAATAACCGTTATGTGATGCTGCACGGCGTCAAC
CGTCACGACAACGATCATCGCAAAGGCCGCGCCGTTGGAATGGATCGCGTCGAGAAAGAT
CTCCAGTTGATGAAGCAGCACAATATCAACTCCGTGCGTACCGCTCACTACCCGAACGAT
CCGCGTTTTTACGAACTGTGTGATATCTACGGCCTGTTTGTGATGGCGGAAACCGACGTC
GAATCGCACGGCTTTGCTAATGTCGGCGATATTAGCCGTATTACCGACGATCCGCAGTGG
GAAAAAGTCTACGTCGAGCGCATTGTTCGCCATATCCACGCGCAGAAAAACCATCCGTCG
ATCATCATCTGGTCGCTGGGCAATGAATCCGGCTATGGCTGTAACATCCGCGCGATGTAC
CATGCGGCGAAACGGCTGGATGACACGCGACTGGTGCATTACGAAGAAGATCGCGATGCT
GAAGTGGTCGATATTATTTCCACCATGTACACCCGCGTGCCGCTGATGAATGAGTTTGGT
GAATACCCGCATCCGAAGCCGCGCATCATCTGTGAATATGCTCATGCGATGGGGAACGGA
CCGGGCGGGCTGACGGAGTACCAGAACGTCTTCTATAAGCACGATTGCATTCAGGGTCAT
TATGTCTGGGAGTGGTGCGACCACGGGATCCAGGCACAGGACGACCACGGCAATGTCTGG
TATAAATTCGGCGGCGACTACGGCGACTATCCCAACAACTATAACTTCTGTCTTGATGGT
TTGATCTATTCCGATCAGACGCCGGGACCGGGCCTGAAAGAGTACAAACAGGTTATCGCG
CCGGTAAAAATCCACGCGCGGGATCTGACTCGCGGCGAGTTGAAAGTCGAAAATAAACTG
TGGTTTACCACGCTTGATGACTACACCCTGCACGCAGAGGTGCGCGCCGAAGGTGAAAGC
CTCGCGACGCAGCAGATTAAACTGCCGGACGTTGCGCCGAACAGCGAAGCCCCCTTGCAG
ATCACGCTGCCGCAGCTGGACGCCCGCGAAGCGTTCCTCAACATTACGGTGACCAAAGAT
TCCCGCACCCGCTACAGCGAAGCCGGACACCCTATCGCCACTTATCAGTTCCCGCTGAAG
GAAAACACCGCGCAGCCAGTGCCTTTCGCACCAAATAATGCGCGTCCGCTGACGCTGGAA
GACGATCGTTTGAGCTGCACCGTTCGCGGCTACAACTTCGCGATCACCTTCTCAAAAATG
AGTGGCAAACCGACATCCTGGCAGGTGAATGGCGAATCGCTGCTGACTCGCGAGCCAAAG
ATCAACTTCTTCAAGCCGATGATGATCGACAACCACAAGCAGGAGTACGAAGGGCTGTGG
CAACCGAATCATTTGCAGATCATGCAGGAACATCTGCGCGACTTTGCCGTAGAACAGAGC
GATGGTGAAGTGCTGATCATCAGCCGCACAGTTATTGCCCCGCCGGTGTTTGACTTCGGG
ATGCGCTGCACCTACATCTGGCGCATCGCTGCCGATGGCCAGGTTAACGTGGCGCTTTCC
GGCGAGCGTTACGGCGACTATCCGCACATCATTCCGTGCATCGGTTTCACCATGGGAATT
AACGGCGAATACGATCAGGTGGCGTATTACGGTCGTGGACCGGGCGAAAACTACGCCGAC
AGCCAGCAGGCTAACATCATCGATATCTGGCGCCAAGCCGTCGATGCCATGTTCGAGAAC
TATCCCTTCCCGCAGAACAACGGTAACCGTCAGCATGTCCGCTGGACGGCACTGACTAAC
CGCCACGGTAACGGTCTGCTGGTGGTTCCGCAGCGCCCAATTAACTTCAGCGCCTGGCAC
TATACCCAGGAAAACATCCACGCTGCCCAGCACTGTAACGAGCTGCAGCGCAGTGATGAC
ATCACCCTGAACCTCGATCACCAGCTGCTTGGCCTCGGCTCCAACTCCTGGGGCAGCGAG
GTGCTGGACTCCTGGCGCGTCTGGTTCCGTGACTTCAGCTACGGCTTTACGTTGCTGCCG
GTTTCTGGCGGAGAAGCTACCGCGCAAAGCCTGGCGTCGTATGAGTTCGGCGCAGGGTTC
TTTTCCACGAATTTGCACACGGAGAATAAGCAATGA

# Drug_Target_1_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_1_General_References:
1540130	Elliott AC, K S, Sinnott ML, Smith PJ, Bommuswamy J, Guo Z, Hall BG, Zhang Y: The catalytic consequences of experimental evolution. Studies on the subunit structure of the second (ebg) beta-galactosidase of Escherichia coli, and on catalysis by ebgab, an experimental evolvant containing two amino acid substitutions. Biochem J. 1992 Feb 15;282 ( Pt 1):155-64.
2515108	Hall BG, Betts PW, Wootton JC: DNA sequence analysis of artificially evolved ebg enzyme and ebg repressor genes. Genetics. 1989 Dec;123(4):635-48.
3939707	Stokes HW, Betts PW, Hall BG: Sequence of the ebgA gene of Escherichia coli: comparison with the lacZ gene. Mol Biol Evol. 1985 Nov;2(6):469-77.
6411710	Fowler AV, Smith PJ: The active site regions of lacZ and ebg beta-galactosidases are homologous. J Biol Chem. 1983 Sep 10;258(17):10204-7.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
129

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
117880

# Drug_Target_1_Name:
Evolved beta-galactosidase subunit alpha

# Drug_Target_1_Number_of_Residues:
1030

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00703	Glyco_hydro_2
PF02836	Glyco_hydro_2_C
PF02837	Glyco_hydro_2_N
PF02929	Bgal_small_N

# Drug_Target_1_Protein_Sequence:
>Evolved beta-galactosidase subunit alpha
MNRWENIQLTHENRLAPRAYFFSYDSVAQARTFARETSSLFLPLSGQWNFHFFDHPLQVP
EAFTSELMADWGHITVPAMWQMEGHGKLQYTDEGFPFPIDVPFVPSDNPTGAYQRIFTLS
DGWQGKQTLIKFDGVETYFEVYVNGQYVGFSKGSRLTAEFDISAMVKTGDNLLCVRVMQW
ADSTYVEDQDMWWSAGIFRDVYLVGKHLTHINDFTVRTDFDEAYCDATLSCEVVLENLAA
SPVVTTLEYTLFDGERVVHSSAIDHLAIEKLTSASFAFTVEQPQQWSAESPYLYHLVMTL
KDANGNVLEVVPQRVGFRDIKVRDGLFWINNRYVMLHGVNRHDNDHRKGRAVGMDRVEKD
LQLMKQHNINSVRTAHYPNDPRFYELCDIYGLFVMAETDVESHGFANVGDISRITDDPQW
EKVYVERIVRHIHAQKNHPSIIIWSLGNESGYGCNIRAMYHAAKALDDTRLVHYEEDRDA
EVVDIISTMYTRVPLMNEFGEYPHPKPRIICEYAHAMGNGPGGLTEYQNVFYKHDCIQGH
YVWEWCDHGIQAQDDHGNVWYKFGGDYGDYPNNYNFCLDGLIYSDQTPGPGLKEYKQVIA
PVKIHARDLTRGELKVENKLWFTTLDDYTLHAEVRAEGETLATQQIKLRDVAPNSEAPLQ
ITLPQLDAREAFLNITVTKDSRTRYSEAGHPIATYQFPLKENTAQPVPFAPNNARPLTLE
DDRLSCTVRGYNFAITFSKMSGKPTSWQVNGESLLTREPKINFFKPMIDNHKQEYEGLWQ
PNHLQIMQEHLRDFAVEQSDGEVLIISRTVIAPPVFDFGMRCTYIWRIAADGQVNVALSG
ERYGDYPHIIPCIGFTMGINGEYDQVAYYGRGPGENYADSQQANIIDIWRSTVDAMFENY
PFPQNNGNRQHVRWTALTNRHGNGLLVVPQRPINFSAWHYTQENIHAAQHCNELQRSDDI
TLNLDHQLLGLGSNSWGSEVLDSWRVWFRDFSYGFTLLPVSGGEATAQSLASYEFGAGFF
STNLHSENKQ

# Drug_Target_1_Reaction:
Hydrolysis of terminal non-reducing beta-D-galactose residues in beta-D-galactosides ALL_REAC (other) R01105 R01678 R01679 R03355 R03616 R04633 R04783 R05112 R05994(G) R06010(G) R06098(G) R06099(G) R06111(G) R06144(G) R06202(G) R07807(G)

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
The wild-type enzyme is an ineffective lactase. Two classes of point mutations dramatically improve activity of the enzyme

# Drug_Target_1_SwissProt_ID:
P06864

# Drug_Target_1_SwissProt_Name:
BGA2_ECOLI

# Drug_Target_1_Synonyms:
EC 3.2.1.23
Lactase

# Drug_Target_1_Theoretical_pI:
5.25

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB00581
